Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies

Seong Cho,Bruce Tan,Noam Cohen,Jody Tversky,Elina Toskala,Scott Nash,Haixing Zhang,Shahid Siddiqui,Asif Khan,Juby Jacob-Nara,Paul Rowe,Yamo Deniz

doi:10.1016/j.jaci.2021.12.483

Dupilumab improves objective, subjective, and health-related quality of life outcomes in chronic rhinosinusitis with nasal polyps (CRSwNP), regardless of BMI ≥30 kg/m2 or weight ≥90 kg: post-hoc analysis of the SINUS-24 and SINUS-52 studies

Seong Cho, Bruce Tan + Show 10 more

https://doi.org/10.1016/j.jaci.2021.12.483

Copy DOI

Journal: Journal of Allergy and Clinical Immunology

Publication Date: Feb 1, 2022

Affiliation: University of South Florida, Northwestern University, University of Pennsylvania, Johns Hopkins Medicine, Johns Hopkins University, Thomas Jefferson University, Regeneron (United States), Sanofi (France), Sanofi (United States)

#Chronic Rhinosinusitis With Nasal Polyps #Outcomes In Chronic Rhinosinusitis + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Dupilumab 300 mg q2w significantly improved endoscopic, radiographic, clinical, and patient-reported outcomes as well as health-related quality of life in patients with CRSwNP in the SINUS-24 and SINUS-52 studies (NCT02912468/NCT02898454). This post-hoc analysis investigated dupilumab’s efficacy in the SINUS studies according to baseline body mass index (BMI) and weight.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Allergy and Clinical Immunology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.